Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2021
This article has no abstract
Epistemonikos ID: b70dcac108e36bd475bf0397d4862cfd5ccc3d7d
First added on: Feb 13, 2025